The results revealed that elevated ACTR3 expression is significantly correlated with negative outcomes in patients diagnosed with adrenocortical carcinoma (ACC), CESC, head and neck squamous cell carcinoma (HNSC), chromophobe renal cell carcinoma (KICH), clear cell renal cell carcinoma (KIRC), papillary renal cell carcinoma (KIRP), acute myeloid leukemia (LAML), lower grade glioma (LGG), hepatocellular carcinoma (LIHC), mesothelioma (MESO), skin cutaneous melanoma (SKCM), and endometrial carcinoma (UCEC). This evidence concerns the gene ACTR3 and cutaneous melanoma.